- Coordinator
- Panepistimio Patron, Greece
- Runs
- 1 March 2027 to 28 February 2030
- Status
- Running
- EU funding
- €1.5m
- Total cost
- —
- Partners
- 5 organisations in 4 countries
- Type
- Coordination and Support Action
- Grant agreement
- 101340916
What the project is doing
In the project's own words, from its summary on CORDIS.
Drug discovery research includes lengthy Design-Make-Test-Analyze (DMTA) cycles that can delay the development and clinical trials of novel drug candidates by months, or even years, if not conducted efficiently. Not only the length of such DMTA cycles, but also flawed collaboration infrastructure between various leading European drug discovery institutes hampers drug discovery timelines, eventually resulting in more patients with serious diseases left untreated.
The TWISTING project aims to leverage on the drug discovery capacity of two widening institutions, University of Patras (UPAT, GR, Coordinator) and National Institute of Research and Innovation (NIRI; former Latvian Institute of Organic Synthesis, LV), based on the excellence of two leaders in the field, ETH Zurich (CH) and University of Oulu (UOULU, FI), to address lengthy DMTA cycles and inefficient drug discovery infrastructures by the WIDERA ‘twinning’ exercise.
In addition, NexMR (CH) will join as a young startup to warrant effective valorization of scientific project results, as well as strengthening engagement with pharmaceutical companies and other industrial stakeholders. Through twinning actions in the project, such as knowledge transfer and short-term staff exchanges, main applicant UPAT and widening partner NIRI will increase their scientific excellence, global network and infrastructure to the highest standards of advanced partners UOULU and ETHZ.
Collectively, the partners will implement measures to improve research management, fundability and dissemination strategies for the widening partners. To validate the newly established research infrastructure, the partners will conduct a mutual drug discovery project on protein-protein interaction (PPI)-centric drug discovery with >80% shorter and more effective DMTA cycles. The results of this project are preclinical drug candidates for difficult PPI-centric targets in the field of oncology, autoimmune diseases or neurodegenerative diseases with a potentially life-saving impact.
The non-scientific project results include capacity-building for research infrastructure at widening partners UPAT and NIRI, transforming them into globally-leading academic institutes for advanced drug discovery. In the long-term, the project is expected to result in significant expertise, employment growth and a renowned international reputation for the widening partners in the context of drug discovery and Life Sciences.
This will set the foundation for a Pan-European research collaboration network for advanced drug discovery, with each partner bringing unique expertise and infrastructure to discover new small molecule drugs for diseases with high unmet needs and leverage the human potential and the institutional capacity of the widening partners.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Panepistimio Patron | Rio Patras | Greece | Coordinator |
| Eidgenoessische Technische Hochschule Zuerich | Zuerich | Switzerland | Participant |
| NexMR AG | Schlieren | Switzerland | Participant |
| Oulun Yliopisto | Oulu | Finland | Participant |
| Valsts zinatniskais instituts ""Nacionalais petniecibas un inovaciju instituts"""" | Riga | Latvia | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI